Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Marinus Pharma CS
(NQ:
MRNS
)
1.300
-0.020 (-1.52%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Marinus Pharma CS
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Marinus Pharmaceuticals Further Strengthens Board of Directors with Appointment of Sarah Noonberg, M.D., Ph.D.
May 17, 2023
From
Marinus Pharmaceuticals
Via
Business Wire
Why Heron Therapeutics Shares Are Trading Lower By 34%? Here Are Other Stocks Moving In Friday's Mid-Day Session
May 12, 2023
Gainers GSI Technology, Inc. (NASDAQ: GSIT) shares surged 108% to $3.4207. GSI Technology is expected to announce financial results for its fiscal fourth quarter after the market close on May 16,...
Via
Benzinga
Marinus Pharma: Q1 Earnings Insights
May 11, 2023
Via
Benzinga
Where Marinus Pharma Stands With Analysts
April 25, 2023
Via
Benzinga
RBC Capital Maintains Outperform Rating for Marinus Pharma: Here's What You Need To Know
March 08, 2023
Via
Benzinga
6 Analysts Have This to Say About Marinus Pharma
March 08, 2023
Via
Benzinga
Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2023 Financial Results
May 11, 2023
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
May 09, 2023
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals to Present at Upcoming Investor Conferences
May 03, 2023
From
Marinus Pharmaceuticals
Via
Business Wire
Earnings Outlook For Marinus Pharmaceuticals
March 06, 2023
Via
Benzinga
Noting Strong Progress On Marinus Pharma's Lead Drug Ganaxolone, Analyst Initiates With 300% Upside
January 20, 2023
Via
Benzinga
Marinus Pharma, Tenacia Biotech Ink Ganaxolone Agreement In China
November 17, 2022
Via
Benzinga
Marinus Pharmaceuticals to Provide Business Update and Report First Quarter 2023 Financial Results on May 11, 2023
April 27, 2023
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals Appoints Marvin H. Johnson, Jr. to its Board of Directors
April 18, 2023
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 06, 2023
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals Receives FDA Orphan Drug Designation for Ganaxolone in the Treatment of Lennox-Gastaut Syndrome
March 22, 2023
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results
March 07, 2023
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
March 06, 2023
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals to Provide Business Update and Report Fourth Quarter 2022 Financial Results on March 7, 2023
February 13, 2023
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 10, 2023
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals to Present at Upcoming Investor Conferences
February 07, 2023
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals Appoints Christine Silverstein to its Board of Directors
January 30, 2023
From
Marinus Pharmaceuticals
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For January 20, 2023
January 20, 2023
Via
Benzinga
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 09, 2023
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2022 ZTALMY® Net Product Revenue and Provides Business Update
January 05, 2023
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
December 09, 2022
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals Announces Presentations and Investor Event at American Epilepsy Society 2022 Annual Meeting
November 30, 2022
From
Marinus Pharmaceuticals
Via
Business Wire
Week In Review: Fosun Signs $840 Million Deal For US Rights To Henlius' PD-1
November 19, 2022
Fosun Pharma announced it has licensed US rights to a PD-1 candidate from Henlius Biotech in an $840 million agreement. Meanwhile, Tenacia Biotechnology in-licensed greater China rights to a seizure...
Via
Talk Markets
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
November 18, 2022
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals Appoints CEO Scott Braunstein, M.D., as Chairman of the Board
November 17, 2022
From
Marinus Pharmaceuticals, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.